Literature DB >> 17301252

Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.

Leah E Mechanic1, Elise D Bowman, Judith A Welsh, Mohammed A Khan, Nobutoshi Hagiwara, Lindsey Enewold, Peter G Shields, Laurie Burdette, Stephen Chanock, Curtis C Harris.   

Abstract

Lung cancer is primarily caused by tobacco smoking, but susceptibility is likely modified by common genetic variation. In response to many forms of cellular stress, including DNA damage, the p53 protein functions to induce cell cycle arrest, DNA repair, senescence, or apoptosis. We hypothesized that common TP53 haplotypes modulate pathways of lung carcinogenesis and lung cancer susceptibility or prognosis. To investigate our hypothesis, 14 polymorphisms in TP53, including haplotype tagging and coding single nucleotide polymorphisms, were genotyped in two studies from the greater Baltimore, Maryland area. One study is a case-control study and the second is a case-only study for which TP53 mutational spectra data are available. African Americans with Pro-T-A-G-G haplotypes of the combined TP53 polymorphisms TP53_01 (rs1042522), TP53_65 (rs9895829), TP53_66 (rs2909430), TP53_16 (rs1625895), and TP53_11 (rs12951053) had both an increased risk for lung cancer (odds ratio, 2.32; 95% confidence interval, 1.18-4.57) and a worsened lung cancer prognosis (hazards ratio, 2.38; 95% confidence interval, 1.38-4.10) compared with those with Arg-T-A-G-T haplotypes. No associations of TP53 polymorphisms with lung cancer were observed in Caucasians. In the case-only study, several polymorphisms in TP53 and TP53 haplotypes, overlapping regions of TP53 associated with risk and prognosis in African Americans, were associated with increased odds of somatic TP53 mutation in lung tumors in Caucasians. In conclusion, common genetic variation in TP53 could modulate lung cancer pathways, as suggested by the association with lung cancer in African Americans and somatic TP53 mutation frequency in lung tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301252     DOI: 10.1158/1055-9965.EPI-06-0790

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

3.  Association study of TP53 polymorphisms with lung cancer in a Korean population.

Authors:  Hae-Yun Jung; Young Mi Whang; Jae Sook Sung; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2008-03-25       Impact factor: 3.172

4.  Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population.

Authors:  Jiang-Ying Ru; Yu Cong; Wen-Bo Kang; Lei Yu; Tin Guo; Jian-Ning Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 5.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

6.  The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.

Authors:  Chunbo Wang; Huan Nie; Yiqun Li; Guiyou Liu; Xu Wang; Shijie Xing; Liping Zhang; Xin Chen; Yue Chen; Yu Li
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

7.  Advancing genomic research and reducing health disparities: what can nurse scholars do?

Authors:  Cheedy Jaja; Robert Gibson; Shirley Quarles
Journal:  J Nurs Scholarsh       Date:  2013-03-01       Impact factor: 3.176

8.  P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.

Authors:  Chao Zhou; Hao Chen; An Wang
Journal:  Tumour Biol       Date:  2013-05-30

9.  Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study.

Authors:  Yun-Ling Zheng; Ourania Kosti; Christopher A Loffredo; Elise Bowman; Leah Mechanic; Donna Perlmutter; Raymond Jones; Peter G Shields; Curtis C Harris
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

10.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.